{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-030997","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2024-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.026028+00:00","generated_at":"2026-06-05T03:34:49.048562+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"SELLAS Life Sciences regains Nasdaq compliance for minimum market value rule","bullets":["Received Nasdaq letter on March 5, 2024 confirming compliance with Listing Rule 5550(b)(2).","Company maintained market value of common stock above $35M for 10 consecutive business days.","Previous non-compliance notice received on December 6, 2023; matter now closed.","Regains compliance before the June 3, 2024 deadline."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-030997","json":"https://secwatch.observer/filing/0001104659-24-030997.json","markdown":"https://secwatch.observer/filing/0001104659-24-030997.md","text":"https://secwatch.observer/filing/0001104659-24-030997.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000110465924030997/0001104659-24-030997-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000110465924030997/tm248024d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T03:34:49.048562+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}